Related Experiment Video
Updated: Jan 21, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
CDK12 inactivation across solid tumors: an actionable genetic subtype
Catherine H Marshall1, Eddie L Imada2, Zhuojun Tang3
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract:
Inactivating CDK12 alterations have been reported in ovarian and prostate cancers and may have therapeutic implications; however, the prevalence of these mutations across other cancer types is unknown. We searched the cBioPortal and GENIE Project (public release v4.1) databases for cancer types with > 200 sequenced cases, that included patients with metastatic disease, and in which the occurrence of at least monoallelic CDK12 alterations was > 1%. The prevalence of at least monoallelic CDK12 mutations was highest in bladder cancer (3.7%); followed by prostate (3.4%), esophago-gastric (2.1%) and uterine cancers (2.1%). Biallelic CDK12 inactivation was highest in prostate cancer (1.8%), followed by ovarian (1.0%) and bladder cancers (0.5%). These results are the first (to our knowledge) to estimate the prevalence of monoallelic and biallelic CDK12 mutations across multiple cancer types encompassing over 15,000 cases.
Insights
The study found that inactivating CDK12 mutations are most common in bladder, prostate, and uterine cancers. These findings are crucial for understanding potential therapeutic strategies across various cancer types.
Area of Science:
- Oncology
- Genetics
- Genomic Medicine
Background:
- Inactivating alterations in Cyclin-Dependent Kinase 12 (CDK12) have been identified in ovarian and prostate cancers.
- These mutations suggest potential therapeutic implications, but their prevalence across diverse cancer types remains largely unknown.
Purpose of the Study:
- To determine the prevalence of monoallelic and biallelic CDK12 mutations across a wide range of cancer types.
- To identify specific cancer types with a higher incidence of CDK12 alterations for further investigation.
Main Methods:
- Utilized the cBioPortal and GENIE Project databases for comprehensive genomic data analysis.
- Focused on cancer types with over 200 sequenced cases, including metastatic disease cohorts.
- Applied a threshold of >1% occurrence for at least monoallelic CDK12 alterations to identify relevant cohorts.
Main Results:
- The highest prevalence of monoallelic CDK12 mutations was observed in bladder cancer (3.7%), followed by prostate (3.4%), esophago-gastric (2.1%), and uterine cancers (2.1%).
- Biallelic CDK12 inactivation was most frequent in prostate cancer (1.8%), followed by ovarian (1.0%) and bladder cancers (0.5%).
- Analysis encompassed over 15,000 cases, providing a broad overview of CDK12 mutation frequencies.
Conclusions:
- This study provides the first comprehensive estimation of CDK12 mutation prevalence across multiple cancer types.
- The findings highlight bladder, prostate, and uterine cancers as key areas for further research into CDK12's role and therapeutic targeting.
- Understanding CDK12 mutation prevalence is essential for developing targeted therapies and improving patient outcomes.
More Related Videos
06:59Subtype-specific Optical Action Potential Recordings in Human Induced Pluripotent Stem Cell-derived Ventricular Cardiomyocytes
Published on: September 27, 2018
10:34Identification of Sleeping Beauty Transposon Insertions in Solid Tumors using Linker-mediated PCR
Published on: February 1, 2013
Related Concept Videos
X-Inactivation
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Activation and Inactivation of G Proteins
Fixed Action Patterns
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...